Long-term Safety and Effectiveness of Levodopa-carbidopa Intestinal Gel Infusion

Launched by HOSPITAL UNIVERSITARI VALL D'HEBRON RESEARCH INSTITUTE · Jul 18, 2018

Keywords

ClinConnect Summary

The following parameters were analyzed prior to LCIG treatment (at baseline), at months one, three, six and twelve, and every year afterwards over a 10-year period:

* Safety:

- Adverse Events (AEs) related to percutaneous endoscopic gastrostomy (PEG) procedures and gastrostomy, infusion device, and treatment. Actions taken to solve them, and reasons for treatment discontinuation and withdrawal.
* Effectiveness:

* Motor fluctuations: Off time in hours recorded in Parkinson's Disease Diary©.
* Dyskinesia and other motor clinical aspects: evaluated with the Unified Parkinson's Disease...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patients with Parkinson's Desease (PD), diagnosed according to diagnostic criteria of the Brain Bank of London - United Kingdom Parkinson's disease Society Brain Bank (Gibb and Lees 1988; Hughes, Daniel et al. 1992; Calne, Snow et al 1992 ; Daniel i Lees 1993; Gelb, Oliver et al., 1999)
• • 2. Patients with PD who respond to levodopa, according to the doctor's opinion. When the values of clinical scales with levodopa treatment achieve a 20-30% improvement in the scores of the Unified Parkinson's Disease Rating Scale (UPDRS). (UPDRS Off - UPDRS On) / UPDRS Off (Merello, Nouzeilles et al., 2002).
• • 3. Patients with PD with a recognized Off and On status (motor fluctuations), confirmed by Parkinson's Disease Diary © (Hauser, Friedlander et al., 2000) at the start of the study (newspapers corresponding to 3 days preceding the initial visit).
• • 4. Patients with PD in the advanced stage with severe motor fluctuations and dyskinesia induced by levodopa, poorly controlled with conventional optimized treatment.
• • 5. Patients with PD in the advanced stage with severe motor fluctuations and dyskinesia induced by levodopa, poorly controlled with other complex treatments (such as apomorphine infusion pumps or ECP).
• • 6. Patients with PD in the advanced state with serious motor fluctuations that present other non-motor complications such as depressive disorder, mild cognitive disorder, pulmonary control disorder, hallucinations and psychotic disorders and episodes of sleep, of moderate severity but , which excludes them from other alternatives to complex treatments, assisted with devices, second-line antiparkinsonians.
• • 7. Patients who are capable, they or their responsible carers and assistants, to learn the treatment with levodopa intestinal infusion and the use of their devices and to guarantee their proper functioning and correct handling.
• • 8. Patients with PD who have been indicated and who have agreed to begin treatment with levodopa intestinal infusion.
• • 9. Patients who have included and granted their consent to participate in the prospective study of habitual clinical practice and have signed an informed consent form to participate in the study.
• • 10. Women who have stopped menstruation naturally 24 months before, or are surgically sterile.
• • 11. Women of childbearing age may participate in the study provided they use a contraceptive method acceptable from a medical point of view (a stable dose of contraceptive drug for at least 3 months or barrier methods: intrauterine device, diaphragm, or combination of condoms and spermicide).
• • Women who are not nursing or are pregnant. Although no human teratogenicity has been described with levodopa treatment, and carbidopa does not cross the placental barrier and does not prevent these patients from interrupting oral levodopa during pregnancy (Merchant, Cohen et al., 1994; Ball i Sagar 1995; von Graevenitz, Shulman et al. 1996; Nomoto, Kaseda et al., 1997); In the event that it is considered GILC will start after pregnancy.
• • 12. Patients attending the external consultation of the Neurology Service (Unit of Movement Disorders) at the Vall d'Hebron University Hospital.
• Exclusion Criteria:
• • 1. Patients who do not suffer from an idiopathic PD. That is, in which the diagnosis of PD is unclear or there is suspicion that there are other Parkinson's syndromes, such as secondary parkinsonism (caused by drugs, toxins, infectious agents, vascular disease, trauma or brain neoplasms), Parkinson plus syndromes (e.g., multi systemic atrophy, progressive supranuclear paralysis, corticosteroidal degeneration) or other neurodegenerative diseases.
• • 2. Contraindications for the use of levodopa, such as narrow angle glaucoma, pheochromocytoma, Cushing syndrome or malignant melanoma history.
• • 3. Treatment with non-selective MAO inhibitors and selective MAO type A inhibitors. These treatments should not be administered simultaneously with levodopa intestinal infusion. They must be taken down at least two weeks before the start of the treatment.
• • 4. Psychiatric disorders, neurological or behavioral disorders that may interfere with the capacity of the subjects to give their informed consent to participate, or interfere with the performance or interpretation of the study; This category also includes serious hallucinations.
• • 5. Cognitive deficiencies or dementias, defined as a score \<24 in the Mini Mental State Exam (MMSE) (Folstein MF, Folstein et al., 1975) or that reach the criteria for the dementia of the Diagnostic and Statistical Manual of Fourth Mental Disorders (DSM-IV) (American Psychiatric Association 2000). Except for a compelling indication that the fluctuations are seriously impaired and correct and successful treatment and supervision can be guaranteed.
• • 6. Abnormal laboratory data of clinical importance or any abnormal laboratory value that may interfere with the evaluation of safety according to the doctor.
• • 7. Current indications of haematological, autoimmune, endocrine, cardiovascular, renal or gastrointestinal disorders of clinical importance that could interfere with the participation of the subject in the study.
• • 8. Background or current suffering of gastrointestinal, liver, kidney or other pathology that may interfere with the absorption, distribution, metabolism or excretion of the study's drug or its evaluation, or interfere with the introduction of the probe system.
• • 9. Medical, laboratory or surgical problems that the doctor considers to be of clinical importance.
• • 10. Subjects in which the placement of a GEP-J probe is contraindicated for treatment with levodopa intestinal infusion or subjects considered to be of high risk for the GEP-J procedure, according to the evaluation performed by the gastroenterologist or the surgeon.
• The contraindications for the placement of the GEP-J probe include, among others, the following processes:
• • 1. Pathological changes in the gastric wall.
• • 2. Impossibility of joining the gastric wall and the abdominal wall.
• • 3. Blood clotting disorders: prothrombin activity less than 60% or INR of 1.4 and platelet count less than 80,000; Anticoagulant or antiaggregant treatment is not a contraindication but should be corrected and suspended before the procedure, due to the risk of bleeding.
• • 4. Pneumonia or severe respiratory failure. It has been suggested that a forced vital capacity of less than 1 liter and a pCO2 greater than 45 mmHg would be associated with an unacceptable mortality with the GEP procedure.
• • 5. Ascites
• • 6. Peritonitis
• • 7. Acute pancreatitis.
• • 8. Paralytic ileus.
• • 9. State of immunodeficiency, neutropenia, HIV, hypogammaglobulinemia, chronic steroid therapy.
• • Except in cases where the indication of treatment with levodopa intestinal infusion is manifestly necessary and will be resorted to the implantation of a surgical gastrostomy.
• • 11. Uncooperative attitude or reasonable probability that the subject does not comply with the treatment and the procedures of the study.
• • 12. Subjects that do not provide their informed consent in writing to participate in the study.